Andrea Charles | 02/17/2011
David Elder, Externalisation Director for GlaxoSmithKline and Pharma IQ Advisory Board Member, joins Andrea Charles from Pharma IQ, to discuss the most critical unmet drug delivery need and the benefits of early formulation testing. Elder shares his insights on how he thinks formulation screening and testing will develop in the next five years and what will be the next big thing in the field.
To continue reading this story Click Here
RECOMMENDED
MSD announces Phase III data on investigational treatment to lower LDL Cholesterol (LDL-C)
2025-11-17
AI for Pharma & Healthcare 2025
2025-06-18
Upcoming Events
Pharma Contract Manufacturing
23 - 25 March 2026
Mercure Hotel MOA Berlin, Germany
Register Now |
View Agenda |
Learn More